Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) SVP Lori M. Henderson sold 30,000 shares of the stock on the open market in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $19.05, for a total transaction of $571,500.00. Following the transaction, the senior vice president now directly owns 44,563 shares in the company, valued at approximately $848,925. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 1.26% during mid-day trading on Wednesday, hitting $19.36. The stock had a trading volume of 196,688 shares. Albany Molecular Research has a 52-week low of $9.71 and a 52-week high of $22.30. The stock’s 50-day moving average is $20.10 and its 200-day moving average is $16.95. The company has a market cap of $600.8 million and a P/E ratio of 38.39.

Albany Molecular Research (NASDAQ:AMRI) last released its earnings data on Tuesday, August 5th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.

AMRI has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.